Your browser is no longer supported. Please, upgrade your browser.
AKCA Akcea Therapeutics, Inc. daily Stock Chart
AKCA [NASD]
Akcea Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.72 Insider Own0.50% Shs Outstand77.10M Perf Week-7.93%
Market Cap1.30B Forward P/E- EPS next Y-1.96 Insider Trans-2.68% Shs Float17.36M Perf Month-13.55%
Income-29.30M PEG- EPS next Q-0.35 Inst Own20.60% Short Float18.10% Perf Quarter-19.89%
Sales340.80M P/S3.81 EPS this Y115.80% Inst Trans-1.98% Short Ratio11.29 Perf Half Y-27.92%
Book/sh6.61 P/B1.97 EPS next Y-20.20% ROA-5.90% Target Price- Perf Year-47.03%
Cash/sh4.22 P/C3.08 EPS next 5Y- ROE-6.70% 52W Range8.00 - 25.66 Perf YTD-23.20%
Dividend- P/FCF12.95 EPS past 5Y19.40% ROI6.60% 52W High-49.30% Beta-
Dividend %- Quick Ratio12.30 Sales past 5Y- Gross Margin94.70% 52W Low62.63% ATR0.79
Employees294 Current Ratio12.60 Sales Q/Q-90.20% Oper. Margin-9.80% RSI (14)35.32 Volatility3.52% 6.08%
OptionableYes Debt/Eq0.00 EPS Q/Q-240.20% Profit Margin-8.60% Rel Volume0.89 Prev Close13.29
ShortableYes LT Debt/Eq0.00 EarningsMay 05 AMC Payout- Avg Volume278.20K Price13.01
Recom2.40 SMA20-8.23% SMA50-13.00% SMA200-22.24% Volume246,617 Change-2.11%
Oct-07-19Upgrade Wells Fargo Market Perform → Outperform
Sep-23-19Downgrade Wells Fargo Outperform → Market Perform $44 → $24
Sep-18-18Initiated Needham Buy $45
Aug-07-18Reiterated Stifel Hold $33
May-11-18Upgrade Wells Fargo Market Perform → Outperform
Mar-19-18Downgrade Wells Fargo Outperform → Market Perform
Mar-15-18Upgrade Wells Fargo Market Perform → Outperform
Feb-27-18Downgrade Wells Fargo Outperform → Market Perform
Feb-27-18Downgrade Stifel Buy → Hold $20
Nov-07-17Reiterated Stifel Buy $19 → $20
Jul-09-20 07:00AM  
Jul-04-20 03:20PM  
Jun-29-20 07:00AM  
Jun-26-20 09:57AM  
08:44AM  
Jun-25-20 09:43AM  
08:46AM  
08:42AM  
Jun-23-20 08:46AM  
Jun-22-20 09:23AM  
09:06AM  
08:36AM  
08:30AM  
Jun-19-20 12:00PM  
10:19AM  
08:41AM  
Jun-17-20 08:30AM  
07:00AM  
Jun-16-20 09:47AM  
Jun-11-20 08:51AM  
Jun-09-20 07:00AM  
Jun-08-20 07:00AM  
Jun-02-20 08:33AM  
Jun-01-20 07:00AM  
May-29-20 09:38AM  
08:53AM  
May-28-20 07:00AM  
May-20-20 09:25AM  
May-19-20 09:30AM  
May-18-20 09:25AM  
07:00AM  
May-15-20 09:25AM  
May-14-20 09:30AM  
May-13-20 09:20AM  
08:00AM  
May-11-20 10:05AM  
08:32AM  
May-09-20 12:00PM  
May-08-20 10:00AM  
May-07-20 10:20AM  
07:00AM  
May-06-20 10:15AM  
01:58AM  
12:01AM  
May-05-20 06:45PM  
04:05PM  
10:15AM  
May-04-20 10:40AM  
May-01-20 10:15AM  
Apr-30-20 09:50AM  
Apr-29-20 01:47PM  
09:50AM  
Apr-28-20 04:50PM  
12:34PM  
Apr-27-20 10:30AM  
06:19AM  
Apr-24-20 10:00AM  
Apr-23-20 10:15AM  
Apr-22-20 09:45AM  
Apr-21-20 10:35AM  
07:00AM  
Apr-20-20 10:45AM  
Apr-18-20 09:55AM  
Apr-17-20 09:40AM  
Apr-16-20 10:00AM  
Apr-15-20 09:35PM  
10:45AM  
Apr-14-20 08:10AM  
Apr-13-20 10:30AM  
Apr-10-20 12:13PM  
11:43AM  
Apr-09-20 10:00PM  
01:02PM  
Mar-31-20 07:10AM  
Mar-25-20 08:16AM  
Mar-24-20 07:00AM  
Mar-18-20 10:12AM  
Mar-13-20 07:00AM  
Mar-11-20 07:00AM  
Mar-09-20 05:19AM  
Feb-28-20 07:00AM  
Feb-27-20 07:55AM  
Feb-26-20 07:00AM  
Feb-25-20 04:05PM  
Feb-18-20 07:00AM  
Feb-13-20 07:00AM  
Jan-28-20 04:05PM  
Jan-23-20 10:35AM  
Jan-22-20 04:29PM  
07:05AM  
Jan-17-20 05:23AM  
Jan-10-20 07:00AM  
Jan-02-20 08:00AM  
Dec-23-19 03:59PM  
Dec-19-19 07:52AM  
Dec-18-19 10:03PM  
Dec-16-19 07:00AM  
Dec-06-19 08:00AM  
Dec-04-19 07:00AM  
Nov-25-19 07:00AM  
Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, an antisense medicine designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome, as well as is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of homozygous familial hypercholesterolemia; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. is a subsidiary of Ionis Pharmaceuticals, Inc.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Patterson Joshua F.General CounselMar 23Sale11.763353,93814,614Mar 25 04:44 PM
Jenne KyleChief Commercial OfficerMar 23Sale11.757799,15352,732Mar 25 04:43 PM
O'Dea LouisChief Medical OfficerMar 23Sale11.753,19837,57961,602Mar 25 04:42 PM
McDevitt DamienChief Executive OfficerMar 23Sale11.759,417110,649245,783Mar 25 04:41 PM
Goldberg Jeff MarcChief Operating OfficerSep 26Option Exercise6.96421,4322,932,747305,560Sep 30 09:26 PM
Soteropoulos PaulaChief Executive OfficerSep 26Option Exercise7.052,061,86114,538,2541,711,079Sep 30 05:52 PM
Boyce SarahPresidentJul 15Sale23.521,81942,78319,888Jul 17 04:52 PM